President Donald Trump’s negotiations with pharmaceutical companies demonstrate how his Art of the Deal approach to governance produces results for working-class Americans. President Trump is the first national leader willing to drain the swamp, taking on powerful lobbyists and special interests to deliver lower prices for patients. Democrats have simply shifted costs from patients to taxpayers, while Republicans have too often been reluctant to take on generous corporate donors. The result has

Tag-uri: Donald Trump